文献速递免疫规划传染病防控与疫情报告

基于纳米凝胶的三价PspA鼻喷疫苗保护猕猴抵抗肺炎链球菌气管攻击

A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
PubMed 文献 · Vaccine · 2021-05-17

本研究开发了含阳离子胆固醇支链淀粉纳米凝胶(cCHP)的三价肺炎链球菌表面蛋白A(PspA)无佐剂鼻喷疫苗,并用适用于人的新型鼻喷装置免疫猕猴。免疫后猕猴产生结合肺炎链球菌表面并触发补体C3沉积的PspA特异性IgG,能抑制肺部炎症并大幅减少肺内细菌数,抵抗气管攻击。

要点

  • cCHP三价PspA鼻喷疫苗在猕猴中诱导功能性IgG并激活补体。
  • 免疫猕猴可抵抗肺炎链球菌气管攻击,肺部炎症受抑、细菌载量骤降。
  • 该疫苗覆盖所有血清型共有的PspA,有望弥补多糖疫苗血清型限制。

核心结论

  • cCHP三价PspA鼻喷疫苗是抗肺炎链球菌感染的有效候选疫苗。

研究设计与样本

  • 临床前研究:用适用于人的新型鼻喷装置,以cCHP三价PspA疫苗鼻喷免疫猕猴,随后行肺炎链球菌气管攻击。

主要发现

  • 鼻喷免疫有效诱导PspA特异性IgG,该IgG结合肺炎链球菌表面并触发补体C3沉积。
  • 免疫猕猴通过抑制肺部炎症和大幅减少肺内细菌数,抵抗肺炎链球菌气管攻击。

临床怎么用

  • 提示鼻喷无佐剂三价PspA纳米凝胶疫苗可作为广谱肺炎链球菌疫苗的候选策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current polysaccharide-based pneumococcal vaccines are effective but not compatible with all serotypes of Streptococcus pneumoniae. We previously developed an adjuvant-free cationic nanogel nasal vaccine containing pneumococcal surface protein A (PspA), which is expressed on the surfaces of all pneumococcal serotypes. Here, to address the sequence diversity of PspA proteins, we formulated a cationic nanogel-based trivalent pneumococcal nasal vaccine and demonstrated the vaccine's immunogenicity and protective efficacy in macaques by using a newly developed nasal spray device applicable to humans. Nasal vaccination of macaques with cationic cholesteryl pullulan nanogel (cCHP)-trivalent PspA vaccine effectively induced PspA-specific IgGs that bound to pneumococcal surfaces and triggered complement C3 deposition. The immunized macaques were protected from pneumococcal intratracheal challenge through both inhibition of lung inflammation and a dramatic reduction in the numbers of bacteria in the lungs. These results demonstrated that the cCHP-trivalent PspA vaccine is an effective candidate vaccine against pneumococcal infections.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nakahashi-Ouchida R, Uchida Y, Yuki Y, et al. A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci. Vaccine. 2021. PMID: 34016473. doi:10.1016/j.vaccine.2021.04.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。